Virus-like particle

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Research, Smallpox, GeoVax, Matrix (biology), Neoplasm, Vaccine, Virus-like particle, ABL, COVID-19, Biotechnology, NIH, Hospital, Security (finance), Congress, Immunity, CGMP, DNA, Therapy, Pfizer, Acute leukemia, AACR, MUC-1, Conference, Vaccination, Safety, Chronic lymphocytic leukemia, Antigen, Patent, Clinical trial, Infection, MVA, SARS-CoV-2, Messenger, Cancer, CLL, Immunodeficiency, Risk, VP40, Death, Patient, HIV, Travel

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

GeoVax Announces Multiple Patent Issuances and Allowances

Retrieved on: 
Tuesday, February 13, 2024
COVID-19, Biotechnology, GeoVax, Matrix (biology), FDA, Cancer, Patent, MUC-1, Vaccine, VP40, Neoplasm, Data, Vaccination, Virus-like particle, Antigen, Intellectual property, Infection, MVA, HIV, DNA

ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.

Key Points: 
  • The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the allowance of the Company’s Patent Application No.
  • The U.S. Patent and Trademark Office issued Patent No.
  • 11,896,657 to GeoVax, pursuant to the Company’s patent application No.
  • David Dodd, GeoVax President and CEO, commented, “These patent actions add to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

Retrieved on: 
Monday, January 8, 2024
IND, Sale, Research, Norovirus, Vaccine, Disease, Mortality, Virus-like particle, SHE, MD, Doctor of Philosophy, Investigational New Drug, VLP, Bioproduct, Safety, Pharmaceutical industry

HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.

Key Points: 
  • HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.
  • As part of the exclusive license agreement, Kangh will supply HIL-216 for use in HilleVax’s near-term clinical trials, including a Phase 1 trial that HilleVax expects to initiate in 2024.
  • “Our bivalent norovirus VLP vaccine candidate, HIL-214, remains the most advanced norovirus vaccine candidate in clinical development, and we are on-track to report topline safety and efficacy data in mid-2024 from our ongoing Phase 2b NEST-IN1 trial.
  • Kangh is also eligible to receive a single-digit tiered royalty on net sales outside of Greater China.

EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001

Retrieved on: 
Monday, December 4, 2023
Guillain–Barré syndrome, Infection, Inflammatory bowel disease, CMO, Multiple sclerosis, Vaccine, Disease, Virus-like particle, Mouse, Human, GMP, EBV, Cancer, Epithelium, CSO, Chronic fatigue syndrome, Epstein–Barr virus, Infectious mononucleosis

The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.

Key Points: 
  • The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • “In addition to a strong preclinical data package, we now have everything in place for the start of clinical trials,” said Axel Polack, M.D., designated CEO of EBViously.
  • It is also known that people infected with EBV are 32 times more likely to develop multiple sclerosis.

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, VLP, Disease, COPD, Acquisition, Heart, AstraZeneca, RSV, Food, Virus-like particle, Security (finance), Incidence, Pneumonia, Human, Risk, US Foods, Protein, Mortality, Vaccination, Fast track (FDA), Patient, Urinary tract infection, Letter, Death, Vaccine, Hepatitis, Infection, Immune Therapy Holdings, University, Virus, Communication, SARS-CoV-2, VWAP, Viral pneumonia, Asthma, Immunity (medical), Schedule, Respiratory syncytial virus, Pharmaceutical industry

Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.

Key Points: 
  • Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
  • Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
  • In Icosavax’s Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.
  • The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023
Medicine, Attention, Glycosylation, Category, Research, Virus-like particle, Biology, Biotechnology, Protein, Insect cell culture, Serum, New Classics Media, Growth, Vaccine, USD, Biopharmaceutical, Cytogenetics, A-DNA, Transfection, Fine chemical

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023
Medicine, Attention, Glycosylation, Category, Research, Virus-like particle, Biology, Biotechnology, Protein, Insect cell culture, Serum, New Classics Media, Growth, Vaccine, USD, Biopharmaceutical, Cytogenetics, A-DNA, Transfection, Fine chemical

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Retrieved on: 
Friday, November 3, 2023
Membrane, CD3, GPCR, RNA, Society for Immunotherapy of Cancer, GPRC5D, Doctor of Philosophy, Poster, Chicken, SITC, Immunotherapy, MPS, Antibody, Path integral molecular dynamics, Virus-like particle, Society, Patient, Integral, BCMA, DNA, Fine chemical, Vaccine

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.

Key Points: 
  • Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.
  • A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.
  • Integral Molecular's oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology.
  • GPRC5D and other antibody assets from Integral Molecular are available for licensing.

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Retrieved on: 
Monday, October 9, 2023
Patent, Infection, Matrix (biology), Cancer, COVID-19, GeoVax, Death, Vaccine, Weight loss, Intellectual property, Survival, Biotechnology, MVA, FDA, Vaccination, Immunization, Virus-like particle, VP40, Viremia

ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.

Key Points: 
  • ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.
  • A recent presentation of data from nonhuman primate studies demonstrated that immunization with GeoVax’s vaccine candidate, GEO-MM01, conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus.
  • GeoVax is currently evaluating study designs to assess the potential for administering different dose levels of the vaccine and different routes of vaccine delivery to optimize utility and efficacy.
  • This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.”